risdiplam

New Three-Year Data for Genentech’s Evrysdi (risdiplam) Show Long-Term Improvements in Survival and Motor Milestones in Babies With Type 1 Spinal Muscular Atrophy (SMA)
BioSpace
Fri, 04/29/22 - 10:30 am
Genentech
Evrysdi
risdiplam
SMA
spinal muscular atrophy
Roche's aim to widen Evrysdi's label nabs speedy FDA review in young spinal muscular atrophy patients
Fierce Pharma
Tue, 01/25/22 - 10:54 am
Roche
Evrysdi
risdiplam
FDA
spinal muscular atrophy
FDA Green-Lights Roche Spinal Muscular Atrophy Drug, First Oral Therapy
Xconomy
Sat, 08/8/20 - 10:56 pm
Roche
risdiplam
SMA
spinal muscular atrophy
FDA
Go or no go? Valuable drugs set for FDA decisions
EP Vantage
Wed, 07/29/20 - 10:54 am
FDA
drug approvals
Novartis
inclisiran
Biomarin
valrox
Roche
risdiplam
GSK
belantamab mafodotin
Gilead Sciences
Galapagos
filgotinib
OptumRx: The 3 drugs that will have the biggest impact on payers, patients in 2020
Beckers Hospital Review
Thu, 06/11/20 - 10:46 pm
OptumRx
Roche
PTC Therapeutics
risdiplam
SMA
NS Pharma
viltolarsen
Duchenne Muscular Dystrophy
Immunomedics
Trodelvy
triple negative breast cancer
Roche shares SMA data ahead of scrap with Biogen, Novartis
Fierce Biotech
Tue, 04/28/20 - 10:59 am
Roche
Biogen
Novartis
SMA
spinal muscular atrophy
risdiplam
clinical trials
Roche’s risdiplam delay a relief for SMA rivals Biogen and Novartis—for now: analyst
Fierce Pharma
Wed, 04/8/20 - 11:03 am
Roche
FDA
risdiplam
Biogen
Spinraza
Novartis
Zolgensma
SMA
FDA delays decision on Roche spinal muscular atrophy drug
Biopharma Dive
Tue, 04/7/20 - 07:14 pm
FDA
Roche
SMA
risdiplam
10 Drugs Expected to Enter the Market This Year Could be Blockbusters, Analysis Says
BioSpace
Mon, 03/9/20 - 11:10 pm
biosimilars
Amgen
Allergan
Roche
Rituxan
Bristol-Myers Squibb
ozanimod
risdiplam
Biomarin
valrox
Roche posts data on SMA rival to drugs from Biogen, Novartis
Fierce Biotech
Thu, 02/6/20 - 10:53 am
Roche
SMA
FDA
risdiplam
Fresh trial data fortify position of Roche's oral therapy in spinal muscular atrophy battleground
Endpoints
Thu, 01/23/20 - 11:57 am
Roche
SMA
FDA
risdiplam
Roche aims to 'underwhelm' with risdiplam price as it enters SMA rivalry with Biogen, Novartis — report
Endpoints
Tue, 01/14/20 - 10:20 am
SMA
Roche
risdiplam
Biogen
Novartis
drug pricing
Novartis pulls rival to Roche’s risdiplam in SMA, says market limited
Pharmaforum
Fri, 12/6/19 - 09:51 am
Novartis
Roche
SMA
risdiplam
branaplam
Roche, PTC will now get an FDA decision on their SMA drug in 6 months — facing off with Biogen, Novartis
Endpoints
Mon, 11/25/19 - 09:52 am
Roche
PTC Therapeutics
SMA
risdiplam
Biogen
Spinraza
Roche sets sights on Novartis, Biogen as SMA trial hits target
Yahoo/Reuters
Mon, 11/11/19 - 10:49 am
Roche
SMA
risdiplam
Biogen
Novartis
clinical trials
What could help biotech close out 2019 stronger? Analysts pick 3 events to watch
Biopharma Dive
Sat, 09/7/19 - 06:38 pm
Amgen
AMG 510
KRAS inhibitors
Roche
PTC Therapeutics
risdiplam
Eylea
Novartis
Threats to Spinraza are mounting, but Biogen still has cards to play
EP Vantage
Mon, 07/1/19 - 07:25 pm
Biogen
SMA
Spinraza
Novartis
Roche
risdiplam
Zolgensma
Roche, PTC post latest SMA data from their attempt to rival Spinraza, Zolgensma
Fierce Biotech
Tue, 05/7/19 - 10:19 am
Roche
PTC Therapeutics
spinal muscular atrophy
risdiplam
Novartis
Zolgensma
Biogen
Spinraza
Genentech Announces New Data for Risdiplam in Spinal Muscular Atrophy in Infants
CP Wire
Wed, 10/3/18 - 09:33 am
Genentech/Roche
risdiplam
spinal muscular atrophy
Genentech Announces New Data for Risdiplam in Spinal Muscular Atrophy in Infants
Wed, 10/3/18 - 09:33 am
Genentech/Roche
risdiplam
spinal muscular atrophy

Pages